|
1）DiMauro S, Hirano M. Mitochondrial encepha-lomyopathies: an update. Neuromuscul Disord. 2005; 15: 276-86
|
|
|
|
2）Taylor RW, Turnbull DM. Mitochondrial DNA mutations in human disease. Nat Rev Genet. 2005; 6: 389-402
|
|
|
|
|
|
3）Tucker EJ, Compton AG, Thorburn DR. Recent advances in the genetics of mitochondrial encephalopathies. Curr Neurol Neurosci Rep. 2010; 10: 277-85
|
|
|
|
|
|
4）Klopstock T. Drug-induced myopathies. Curr Opin Neurol. 2008; 21: 590-5
|
|
|
|
|
|
5）Apostolova N, Blas-Garcia A, Esplugues JV. Mitochondrial interference by anti-HIV drugs: mechanisms beyond Pol-γ inhibition. Trends Pharmacol Sci. 2011; 32: 715-25
|
|
|
|
|
|
6）Mastaglia FL, Needham M. Update on toxic myopathies. Curr Neurol Neurosci Rep. 2012; 12: 54-61
|
|
|
|
|
|
7）Dogue A, Bagheri H. Detection and incidence of muscular adverse drug reactions: a prospective analysis from laboratory signals. Eur J Clin Pharmacol. 2004; 60: 285-92
|
|
|
|
|
|
8）Baker SK, Tarnopolsky MA. Statin myopathies: pathophysiologic and clinical perspectives. Clin Invest Med. 2001; 24: 258-72
|
|
|
|
|
|
9）Evans M, Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf. 2002; 25: 649-63
|
|
|
|
|
|
10）Thompson PD, Clarkson P. Statin-associated myopathy. JAMA. 2003; 289: 1681-90
|
|
|
|
|
|
11）Dalakas MC. Peripheral neuropathy and anti-retroviral drugs. J Perphr Nerv Syst. 2001; 6: 14-20
|
|
|
|
|
|
12）Okamoto Y, Higuchi I, Sakiyama Y, et al. A new mitochondria-related disease showing myopathy with episodic hyper-creatine kinase-emia. Ann Neurol. 2011; 70: 486-92
|
|
|
|
|
|
13）Hirata K, Nakagawa M, Higuchi I, et al. Adult onset limb-girdle type mitochondrial myopathy with a mitochondrial DNA np8291 A-to-G substi-tution. J Hum Genet. 1999; 44: 210-4
|
|
|
|
|
14）Shoffner JM, Lott MT, Lezza AM, et al. Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNA(Lys) mutation. Cell. 1990; 61: 931-7
|
|
|
|
|
|
15）Cutler DJ, Zwick ME, Carraquillo MM, et al. High throughput validation detection and geno-typing using microarrays. Genome Res. 2001; 11: 1913-25
|
|
|
|
|
|
16）Kong QP, Bandelt HJ, Sun C, et al. Updating the East Asian mtDNA phylogeny: a prerequisite for the identification of pathogenic mutations. Hum Mol Genet. 2006; 15: 2076-86
|
|
|
|
|
|
17）Ohno K, Tanaka M, Sahashi T, et al. Mito-chondrial DNA deletions in inherited recurrent myoglobinuria. Ann Neurol. 1991; 29: 364-9
|
|
|
|
|
|
18）Melberg A, Holme E, Oldfors A, et al. Rhabdo-myolysis in autosomal dominant progressive external ophthalmoplegia. Neurology. 1998; 50: 299-300
|
|
|
|
|
|
19）Karadimas CL, Greenstein P, Sue CM, et al. Recurrent myoglobinuria due to a nonsense mutation in the COX I gene of mitochondrial DNA. Neurology. 2000; 55: 644-9
|
|
|
|
|
|
20）Andreu AL, Hanna MG, Reichmann H, et al. Exercise intolerance due to mutations in the cytochrome b gene of mitochondrial DNA. N Engl J Med. 1999; 341: 1037-44
|
|
|
|
|
|
21）Qu J, Li R, Zhou X, et al. The novel A4435G mutation in the mitochondrial tRNAMet may modulate the phenotypic expression of the LHON-associated ND4 G11778A mutation. Invest Ophthalmol Vis Sci. 2006; 47: 475-83
|
|
|
|
|
|
22）Cai W, Fu Q, Zhou X, et al. Mitochondrial variants may influence the phenotypic mani-festation of Lebers hereditary optic neuropathy-associated ND4 G11778A mutation. J Genet Genomics. 2008; 35: 649-55
|
|
|
|
|
|
23）Mimaki M, Hatakeyama H, Ichiyama T, et al. Different effects of novel mtDNA G3242A and G3244A base changes adjacent to a common A3243G mutation in patients with mitochondrial disorders. Mitochondrion. 2009; 9: 115-22
|
|
|
|
|
|
24）Chariot P, Gherardi R. Myopathy and HIV infec-tions. Curr Opin Rheumatol. 1995; 7: 497-502
|
|
|
|
|
|
25）Masanes F, Barrientos A, Cebrian M, et al. Clinical, histological and molecular reversibility of zidovudine myopathy. J Neurol Sci. 1998; 159: 226-8
|
|
|
|
|
|
26）Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med. 1995; 1: 417-22
|
|
|
|
|
|
27）Finsterer J, Segall L. Drugs interfering with mitochondrial disorders. Drug Chem Toxicol. 2010; 33: 138-51
|
|
|
|
|
|
28）Kallianpur AR, Hulgan T. Pharmacogenetics of nucleoside reverse-transcriptase inhibitor-asso-ciated peripheral neuropathy. Pharmacogenomics. 2009; 10: 623-7
|
|
|
|
|